covid
Buscar en
Angiología
Toda la web
Inicio Angiología Chlamydia pneumoniae y enfermedad cerebrovascular
Información de la revista
Vol. 53. Núm. 2.
Páginas 72-83 (enero 2001)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 53. Núm. 2.
Páginas 72-83 (enero 2001)
Acceso a texto completo
Chlamydia pneumoniae y enfermedad cerebrovascular
Chlamydia pneumoniae and cerebrovascular disease
Chlamydia pneumoniae e doença vascular cerebral
Visitas
2236
J. Linares-Palominoa,
Autor para correspondencia
jlinaresp@seacv.org

Correspondencia: Servicio de Angiología y Cirugía Vascular. Hospital Clínico Universitario San Cecilio de Granada. Av. Dr. Oloriz, 16. E-18012 Granada. Fax: +34 958 271931
, J. Gutiérrez-Fernándezb, C. López-Espadaa, E. Ros-Díea, J. Moreno-Escobara, T. Pérezc, M. Rodríguez-Fernándezb, M.a C. Maroto-Velab
a Servicio de Angiología y Cirugía Vascular. Hospital Clinico Universitario San Cecilio. Granada
b Servicio de Microbiología. Hospital Clinico Universitario San Cecilio. Granada
c Departamento deMicrobiologia. Universidad de Cádiz. Cádiz,España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen
Introducción

La Chlamydia pneumoniae se ha relacionado con la enfermedad arteriosclerótica extracraneal, tanto por estudios seroepidemiológicos como histológicos. Realizamos un estudio de casos y controles para determinar la seroprevalencia de infección crónica por C. pneumoniae, y la detección de la bacteria en biopsias arteriales.

Pacientes y métodos

El grupo de casos estuvo formado por 26 pacientes con estenosis carotídea subsidiaria de tratamiento quirúrgico. Los controles fueron 50 individuos sometidos a cirugía de varices. Se ajustaron los grupos por edad, sexo y tabaquismo. De ambos grupos se obtuvieron muestras serológicas, donde se determinaron anticuerpos IgG frente a MOMP de C. pneumoniae por microinmunofluorescencia y ELISA. Se obtuvo biopsia arterial en los casos de placa de ateroma carotídeo y en los controles de la arteria pudenda externa. Sobre las biopsias se realizó reacción en cadena de polimerasa utilizando los primers: HL1, HM1 y HR1. Se midió el nivel de fibrinógeno como marcador de inflamación crónica.

Resultados

La seroprevalencia de infección crónica por C. pneumoniae por microinmunofluorescencia para IgG>1:32 fue: 69,23% en casos y 24% en controles (OR: 7,12; IC al 95%: 2,4720,48). Por ELISA la seroprevalencia fue: 76,92 en casos y 16% en controles (OR: 17,5; IC al 95%: 5,3557,23). El ADN de C. pneumoniae se detectó en 18 casos (69,23%) y en 6 controles (12%) (p<0,0001, ji al cuadrado). No se pudo establecer correlación entre los resultados serológicos e histológicos. Los nivelesdefibrinógenonomostrarondiferenciasentre los grupos.

Conclusión

Nuestros resultados apoyan la hipótesis sobre la participación de C. pneumoniae en la etiopatogenia de la arteriosclerosis cerebral extracraneal.

Palabras clave:
Anticuerpo
Aterosclerosis
Chlamydia pneumoniae
Estenosiscarotídea
Estudio de casos y controles
Reacción en cadena de la polimerasa
Summary
Introduction

Chlamydia pneumoniae has relationship with atherosclerosis of carotid artery by seroepidemiological studies and by demonstration of the bacteria in ateromata. We made a case-control study to know the seroprevalence of chronic infection of C. pneumoniae and the presence of the bacteria in arterial biopsies.

Patients and methods

The cases group was constituted by 26 patients undergoing carotid surgery. In the control group there were 50 patients without atherosclerosis and who underwent shipping of their varicose veins. There were matched for sex, age and smoking. We obtained serum samples to determinate IgG antibodies against MOMP by MIF and ELISA. In the cases group, we got the arterial biopsies from carotid artery, and from pudendal arteries in control group. We determinated chlamydial DNA on the biopsies by heminested PCR (primers: HL1, HM1, HR1). We measured fibrinogen in both groups.

Results

By MIF technique, the seroprevalence was (IgG>1:32) 69,23% cases versus 24% controls (OR: 7.12. CI: 2.4720.48).The ELISA showed 76.92% of seropositivity in cases versus 16% in controls (OR: 17.5, CI: 95%:5.3557.23). The DNA of C. pneumoniae was found in 18 cases and 6 controls, (p<0.0001, χ2). We did not find any relationship between fibrinogen levels and groups.

Conclusion

We think that there is a relationship between chronic infection with C. pneumoniae and carotid atherosclerosis.

Key words:
Antibody
Atherosclerosis
Carotid stenosis
Case-control studies
Chlamydiapneu-moniae
Polymerase chain reaction
Resumo
Introdução

A Chlamydia pneumoniae foi associada à doença arteriosclerótica extra-craniana, tanto por estudos seroepidemiológicos como histológicos. Realizámos um estudo de caso controlo, para determinar a seroprevalência de infecção crónica por C. pneumoniae, e detectar a bactéria em biopsias arteriais.

Doentes e métodos

O grupo de casos era formado por 26 doentes com estenose carotídea necessitando tratamento cirúrgico. O grupo de controlo era constituído de 50 indivíduos submetidos a cirurgia varicosa. Os grupos foram determinados por idade, sexo e tabagismo. De ambos os grupos obtiveram-se amostras serológicas a partir das quais se determinaram os anticorpos IgG contra a MOMP da C. pneumoniae por microimunofluorescência e ELISA. Obteve-se biopsia arterial de placa de ateroma carotídeo, nos casos e nos controlos, da artéria pudenda externa. Nas biopsias realizou-se a reacção de polimerase em cadeia, utilizando os primers: HL-1, HM-1 e HR-1. Utilizou-se o nível de fibrinogénio, como marcador de inflamação crónica.

Resultados

A seroprevalência de infecção crónica por C. pneumoniae pormicroimunofluorescência para IgG>1:32 foi: 69,23% nos casos e 24% nos controlos (OR: 7,12; IC a 95%: 2,47-20,48). Por ELISA, a seroprevalência foi: 76,92 nos casos e de 16% nos controlos (OR: 17,5; IC a 95%: 5,35-57,23). O ADN da C. pneumoniae foi detectado em 18 casos (69,23%) e em 6 controlos (12%) (p<0,0001 Chi quadrado). Não foi possível estabelecer uma correlação entre os resultados serológicos e histológicos. Os níveis de fibrinogénio não evidenciaram diferenças entre os grupos.

Conclusão

Os nossos resultados apoiam a hipótese da participação de C. pneumoniae na etiopatogénese da arteriosclerose cerebral extra-craniana.

Palavras chave:
Anticorpo
Aterosclerose
Chlamydia pneumoniae
Ensaioscaso-controlo
Estenose carotídea
Reacção de polimerase em cadeia
El Texto completo está disponible en PDF
Bibliografía
[1.]
Osler W..
Diseases of the arteries.
Modern medicine: its practice and theory, pp. 429-447
[2.]
Fabricant C.G..
Atherosclerosis: the consequence of infection with a herpes virus.
Adv Vet Sci Comp Med, 30 (1985), pp. 39-66
[3.]
Syrjánen J., Valtonen V.V., Livanainen M., Kaste M., Huttunen J.K..
Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients.
Br Med J, 296 (1988), pp. 1156-1160
[4.]
Blasi F., Denti F., Erba M., Cosentini R., Raccanelli R., Rinaldi A., et al.
Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms.
J Clin Microbiol, 34 (1996), pp. 2766-2769
[5.]
Saikku P., Leinonen M., Mattila K., Ekman M.R., Nieminen M.S., Mákelá P.H., Huttunen J.K., Valtonen V..
Serologic evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.
Lancet, 11 (1988), pp. 983-986
[6.]
Thom D.H., Wang S.P., Grayston J.T., Siscovick D.S., Stewart D.K., Kronmal R.A., et al.
Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease.
Arterioscler Thromb, 11 (1991), pp. 547-551
[7.]
Saikku P., Leinonen M., Tenkanen L., Linnanmáki E., Ekman M.R., Manninen V., et al.
Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study.
Ann Intern Med, 116 (1992), pp. 273-278
[8.]
Leinonen M., Linnanmaki, Mattila K., Nieminen M.S., Valtonen V., Leirisalorepo M., Saikku P..
Circulating immune completes containing chlamydial lipopolysaccharide in acute myocardial infarction.
Microb Pathogen, 9 (1990), pp. 67-73
[9.]
Shor A., Kuo C.C., Patton D.L..
Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques.
S Afr Med J, 82 (1992), pp. 158-161
[10.]
Wong Y.K., Gallagher P.J., Ward M.E..
Chlamydia pneumoniae and atherosclerosis.
Heart, 81 (1999), pp. 232-238
[11.]
Gupta S., Leatham E..
The relation between C. pneumoniae and atherosclerosis.
Heart, 77 (1997), pp. 7-8
[12.]
Gutiérrez J., Linares-Palomino J., Rodríguez M., Maroto M.C..
Chlamydia pneumoniae y su relación con la arteriosclerosis humana.
Rev Invest Clin, 52 (2000), pp. 482-486
[13.]
North American Symptomatic Carotid Endarterectomy Trial (NASCET).
N Engl J Med, 226 (1991), pp. 3289-3294
[14.]
Asymptomatic Carotid Atherosclerotic Study (ACAS).
JAMA, 273 (1995), pp. 1421-1428
[15.]
Campbell L.A., Pérez-Melgosa M., Hamilton D., Kuo C.C., Grayston J.T..
Detection of C. pneumoniae by polymerase chain reaction.
J Clin Microbiol, 30 (1992), pp. 434-439
[16.]
Hahn D.L., Golubjatnikov R..
Smoking is a potential confounder of the C. pneumoniae coronary artery disease association.
Arterioscler Thromb, 12 (1992), pp. 945-947
[17.]
Mendall M.A., Carrington D., Strachan D., Patel P., Molineaux N., Levy J., et al.
C. pneumoniae: risk factors for seropositivity and association with coronary heart disease.
J Infect, 30 (1995), pp. 121-128
[18.]
Mazzoli S., Tofani N., Fantini A., Semplici F., Bandini F., Salvi A., Vergassola R..
Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up.
Am Heart J, 135 (1998), pp. 15-20
[19.]
Ossewaarde J.M., Feskens E.J., De Vries A., Vallinga C.E., Kromhout D..
Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not.
Epidemiol Infect, 120 (1998), pp. 93-99
[20.]
Tiran A., Tio R.A., Ossewaarde J.M., Tiran B., Den Heijer P., The T.H., Wilders-Truschnig M.M..
Coronary angioplasty induces rise in Chlamydia pneumoniae-specific antibodies.
J Clin Microbiol, 37 (1999), pp. 1013-1017
[21.]
Korner I., Blatz R., Wittig I., Pfeiffer D., Ruhlmann C..
Serological evidence of Chlamydia pneumoniae lipopolysaccharide antibodies in atherosclerosis of various vascular regions.
[22.]
Melnick S.L., Shahar E., Folsom A.R., Grayston J.T., Sorlie P.D., Wang S.P., Szklo M..
Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators.
Am J Med, 95 (1993), pp. 499-504
[23.]
Wimmer M.L., Sandmann-Strupp R., Saikku P., Haberl R.L..
Association of chlamydial infection with cerebrovascular disease.
Stroke, 27 (1996), pp. 2207-2210
[24.]
Cook P.J., Honeybourne D., Lip G.Y., Beevers D.G., Wise R., Davies P..
Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project.
Stroke, 29 (1998), pp. 404-410
[25.]
Esposito G., Blasi F., Allegra L., Chiesa R., Melissano G., Cosentini R., et al.
Demonstration of viable Chlamydia pneumoniae in atherosclerotic plaques of carotid arteries by reverse transcriptase polymerase chain reaction.
Ann Vasc Surg, 13 (1999), pp. 421-425
[26.]
Fagerberg B., Gnarpe J., Gnarpe H., Agewall S., Wikstrand J..
Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension.
Stroke, 30 (1999), pp. 299-305
[27.]
Markus H.S., Sitzer M., Carrington D., Mendall M.A., Steinmetz H..
Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis.
Circulation, 100 (1999), pp. 832-837
[28.]
Coles K.A., Plant A.J., Riley T.V., Smith D.W., McQuillan B.M., Thompson P.L..
Lack of association between seropositivity to Chlamydia pneumoniae and carotid atherosclerosis.
Am J Cardiol, 84 (1999), pp. 825-828
[29.]
Nieto F.J., Folsom A.R., Sorlie P.D., Grayston J.T., Wang S.P., Chambless L.E..
Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study.
Am J Epidemiol, 150 (1999), pp. 149-156
[30.]
Maass M., Bartels C., Engel P., Mamat U., Sievers H.H..
Endovascular presence of viable C. pneumoniae is a common phenomenon in coronary artery disease.
JACC, 31 (1998), pp. 827-832
[31.]
Chiu B., Viira E., Tucker W., Fong I.W..
Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery.
Circulation, 96 (1997), pp. 2177-2248
[32.]
Paterson D.L., Hall J., Rasmussen S.J., Timms P..
Failure to detect Chlamydia pneumoniae in atherosclerotic plaques of Australian patients.
Pathology, 30 (1998), pp. 169-172
[33.]
Ross R..
Atherosclerosis-an inflammatory disease.
N Engl J Med, 340 (1999), pp. 115-126
[34.]
Grayston J.T., Kuo C.C., Coulson A.S., Campbell L.A., Lawrence R.D., Lee M.J., Strandness E.D., Wang S.P..
Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery.
Circulation, 92 (1995), pp. 3397-3400
[35.]
Maass M., Krause E., Engel P.M., Kruger S..
Endovascular presence of Chlamydia pneumoniae in patients with hemodynamically effective carotid artery stenosis.
Angiology, 48 (1997), pp. 699-706
[36.]
Maass M., Bartels C., Kruger S., Krause E., Engel P.M., Dalhoff K..
Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease.
Atherosclerosis, 140 (1998), pp. S25-S30
[37.]
Nadrchal R., Makristathis A., Apfalter P., Rotter M., Trubel W., Huk I., et al.
Detection of Chlamydia pneumoniae DNA in atheromatous tissues by polymerase chain reaction.
Wien Klin Wochenschr, 26 (1999), pp. 153-156
[38.]
Jantos C.A., Nesseler A., Waas W., Baumgartner W., Tillmanns H., Haberbosch W..
Low prevalence of Chlamydia pneumoniae in atherectomy specimens from patients with coronary heart disease.
Clin Infect Dis, 28 (1999), pp. 988-992
[39.]
Yamashita K., Ouchi K., Shirai M., Gondo T., Nakazawa T., Ito H..
Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery.
Stroke, 29 (1998), pp. 773-778
[40.]
Chiu B..
Multiple infections in carotid atherosclerotic plaques.
Am Heart J, 138 (1999), pp. S534-S536
[41.]
Mosorin M., Surcel H.M., Laurila A., Lehtinen M., Karttunen R., Juvonen J., et al.
Detection of Chlamydia pneumoniae-reactive T lymphocytes in human atherosclerotic plaques of carotid artery.
Arterioscler Thromb Vasc Biol, 20 (2000), pp. 1061-1067
[42.]
Yamashita K., Ouchi K., Shirai M., Gondo T., Nakazawa T., Ito H..
Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery.
Stroke, 29 (1998), pp. 773-778
[43.]
Ong G., Thomas B.J., Mansfield A.O., Davidson B.R., Taylor-Robinson D..
Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications.
J Clin Pathol, 49 (1996), pp. 102-106
[44.]
Jackson L.A., Campbell L.A., Schmidt R.A., Kuo C.C., Cappuccio A.L., Lee M.J., Grayston J.T..
Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis.
Am J Pathol, 150 (1997), pp. 1785-1790
[45.]
Maass M., Gieffers J., Krause E., Engel P.M., Bartels C., Solbach W..
Poor correlation between microimmunofluorescence serology and polymerase chain reaction for detection of vascular Chlamydia pneumoniae infection in coronary artery disease patients.
Med Microbiol Immunol (Berl), 187 (1998), pp. 103-106
[46.]
Patel P., Mendall M.A., Carrington D., Strachan D.P., Leatham E., Molineaux N., et al.
Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors.
Br Med J, 311 (1995), pp. 711-714
[47.]
Jackson L.A., Campbell L.A., Kuo C.C., Lee A., Grayston J.T..
Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen.
J Infect Dis, 176 (1997), pp. 292-295
[48.]
Kaukoranta-Rolvanen S.S., Ronni T., Leinonen M., Saikku P., Laitinen K..
Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae.
Microb Pathog, 21 (1996), pp. 407-411
[49.]
Laitinen K., Laurila A.L., Leinonen M., Saikku P..
Reactivation of Chlamydia pneumoniae infection in mice by cortisone treatment.
Infect Immunol, 64 (1996), pp. 1488-1490
[50.]
Mazzoli S., Tofani N., Fantini A., Semplici F., Bandini F., Salvi A., Vergassola R..
Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up.
Am Heart J, 135 (1998), pp. 15-20
[51.]
Gaydos C.A., Summersgill J.T., Sahney N.N., Ramírez J.A., Quinn T.C..
Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells and aortic artery smooth muscle cells.
Infect Immunol, 64 (1996), pp. 1614-1620
[52.]
Molestina R.E., Miller R.D., Ramírez J.A., Summersgill J.T..
Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes.
Infect Immunol, 67 (1999), pp. 1323-1330
[53.]
De Caterina R., Libby P., Peng H.B..
Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.
J Clin Invest, 96 (1995), pp. 60-68
[54.]
Helme S., Juvonen T., Laurila A., Juvonen J., Mosotin M., Saikku P., Surcel H.M..
Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms.
Eur J Clin Invest, 29 (1999), pp. 546-552
[55.]
Kol A., Bourcier T., Lichtman A.H., Libby P..
Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages.
J Clin Invest, 103 (1999), pp. 571-577
Copyright © 2001. SEACV
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos